Dame JB, Williams JL, McCutchan TF, Weber JL, Wirtz RA, Hockmeyer WT, Maloy WL, Haynes JD, Schneider I, Roberts D, Sander GS, Reddy EP, Diggs CL, Miller LH. 1984. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 225(4662):593–599.

Davis JR. 1994. Laboratory methods for the conduct of experimental malaria challenge of volunteers. Vaccine 12(4):321–327.

Desjardins RE, Canfield CJ, Haynes JD, Chulay JD. 1979. Quantitative assessment of anti-malarial activity in vitro by a semiautomated microdilution technique. Antimicrobial Agents and Chemotherapy 16(6):710–718.

Doolan DL, Hoffman SL. 2000. The complexity of protective immunity against liver-stage malaria. Journal of Immunology 165(3):1453–1462.

Downs WG, Harper PA, Lisamsky ET. 1947. Malaria and other insect-borne diseases in the South Pacific Campaign, 1942-1945. II Epidemiology of insect-borne diseases in Army troops. American Journal of Tropical Medicine 27:69–89.

Dunachie SJ, Hill AV. 2003. Prime-boost strategies for malaria vaccine development. Journal of Experimental Biology 206(Pt 21):3771–3779.

Edozien JC. 1961. The effect of malaria on the serum gamma globulin concentration in Africans. West African Medical Journal 10:304–310.

Ellis J, Ozaki LS, Gwadz RW, Cochrane AH, Nussenzweig V, Nussenzweig RS, Godson GN. 1983. Cloning and expression in E. coli of the malarial sporozoite surface antigen gene from Plasmodium knowlesi. Nature 302(5908):536–538.

Enea V, Ellis J, Zavala F, Arnot DE, Asavanich A, Masuda A, Quakyi I, Nussenzweig RS. 1984. DNA cloning of Plasmodium falciparum circumsporozoite gene: Amino acid sequence of repetitive epitope. Science 225(4662):628–630.

Epstein JE, Charoenvit Y, Kester KE, Wang R, Newcomer R, Fitzpatrick S, Richie TL, Tornieporth N, Heppner DG, Ockenhouse C, Majam V, Holland C, Abot E, Ganeshan H, Berzins M, Jones T, Freydberg CN, Ng J, Norman J, Carucci DJ, Cohen J, Hoffman SL. 2004. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. Vaccine 22(13–14):1592–1603.

Ferreira A, Schofield L, Enea V, Schellekens H, van der Meide P, Collins WE, Nussenzweig RS, Nussenzweig V. 1986. Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. Science 232(4752):881–884.

Fries LF, Gordon DM, Schneider I, Beier JC, Long GW, Gross M, Que JU, Cryz SJ, Sadoff JC. 1992. Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A. Infection and Immunity 60(5):1834–1839.

Garcon N, Heppner DG, Cohen J. 2003. Development of RTS,S/AS02: A purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Reviews of Vaccines 2(2):231–238.

Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan MS, Nene V, Shallom SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin DM, Fairlamb AH, Fraunholz MJ, Roos DS, Ralph SA, McFadden GI, Cummings LM, Subramanian GM, Mungall C, Venter JC, Carucci DJ, Hoffman SL, Newbold C, Davis RW, Fraser CM, Barrell B. 2002a. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419(6906):498–511.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement